VOTE GOLD PROXY GUYS Change is Needed Now
Dr. Raza Bokhari, FSD’s Chief Executive Officer, and his hand picked board members have:
- failed to address the dramatic loss of shareholder value, with the Company’s shares trading over 97% lower than when Dr. Bokhari was appointed Interim Chief Executive Officer;
- massively diluted shareholder interests by issuing almost 16 million shares at low prices, increasing the number outstanding by over 83% in just seven weeks;
- awarded over $5.7 million of bonus share compensation to Dr. Bokhari in February 2021 for services yet to be provided and close to $1 million in shares and/or cash to the other directors (Stephen Buyer, Robert Ciaruffoli, James Datin, Gerald Goldberg and Larry Kaiser), the latter amount being almost twice the previous year’s compensation;
- caused FSD to reimburse Dr. Bokhari’s privately owned and controlled company for over $1.4 million of expenses in 2020, with limited transparency or explanation;
- failed to effectively implement the Company’s business plan to become a pharmaceutical and biotechnology company, having to date failed to meet any of their modest stated goals; and
- denied shareholders any say on the change of the Company’s strategic focus, failing to hold a shareholders’ meeting in 2020 and seeking to delay holding a meeting in 2021.